[Comparative study between 0.025% ketotifen fumarate and 0.1% olopatadine hydrochloride in the treatment of vernal keratoconjunctivitis].
OBJECTIVE
To compare the topical use of 0.025% ketotifen fumarate and 0.1% olopatadine hydrochloride in the treatment of patients with vernal keratoconjunctivitis.


METHODS
A study performed in one center, simple masked, parallel-group compared ketotifen and olopatadine. These patients were evaluated on four visits during the treatment (days 1, 7, 14 and 21), defined by ratings scores. Adverse events were the main variable of safety rating.


RESULTS
On evaluating ocular itching, burning, tearing, conjunctival hyperemia, mucous discharge and photophobia, the ketotifen group showed a significant improvement of total signs and symptoms (p<0.05). Between the baseline and the 2nd visit, treatment with olopatadine resulted in decreased burning, but after the 4th visit, ketotifen was slightly better. Sand sensation, papillae and Horner-Trantas dots were not significantly different in both groups.


CONCLUSIONS
Both drugs were efficient and safe relieving the main symptoms and signs of vernal keratoconjunctivitis. Between the same timepoints, there was a significant difference in favor of ketotifen-treated patients (p<0.05), showing improvement of itching, tearing, conjunctival hyperemia, mucous discharge and photophobia.
Hida
Wilson Takashi
WT
Departamento de Oftalmologia, Faculdade de Ciências Médicas, Santa Casa de Misericórdia de São Paulo, Rua Afonso de Freitas 488, São Paulo, SP, CEP 04006-052 Brazil. witaks@yahoo.com.br
Nogueira
Daniel Cruz
DC
Schaefer
Arthur
A
Dantas
Paulo Elias Correa
PE
Dantas
Maria Cristina Nishiwaki
MC
D000287:Administration, Topical; D018926:Anti-Allergic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016009:Chi-Square Distribution; D002648:Child; D002675:Child, Preschool; D003233:Conjunctivitis, Allergic / Q000188:drug therapy*; D003990:Dibenzoxepins / Q000009:adverse effects / Q000627:therapeutic use*; D005128:Eye Diseases / Q000209:etiology*; D005260:Female; D006801:Humans; D007665:Ketotifen / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D000069605:Olopatadine Hydrochloride; D009883:Ophthalmic Solutions / Q000009:adverse effects / Q000627:therapeutic use; D011537:Pruritus / Q000209:etiology; D012621:Seasons; D016037:Single-Blind Method; D018709:Statistics, Nonparametric; D013666:Tears / Q000187:drug effects; D013997:Time Factors; D016896:Treatment Outcome
D018926:Anti-Allergic Agents; D003990:Dibenzoxepins; D009883:Ophthalmic Solutions; D000069605:Olopatadine Hydrochloride; D007665:Ketotifen